Softwr

AI · head to head

LatchBio vs Zimpler

LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Free plan
No
Zimpler logo

Zimpler

APIs

Nordic and Brazilian account-to-account payments for regulated high-risk sectors

From
On request
Free plan
No

The short version

  • Only LatchBio lists agent driven analysis; only Zimpler lists bank payments.
  • Prices and features on this page were last checked on 1 September 2026.

Where they differ

Only the attributes on which LatchBio and Zimpler actually diverge.

Attributes where LatchBio and Zimpler differ
AttributeLatchBioZimpler
PlatformsWebWeb, API
CategoryAIAPIs

Identical on both: starting price (On request), pricing model (Quote), free tier (No).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

Only in Zimpler

  • Bank payments
  • BankID identity
  • Payouts
  • Recurring payments
  • Risk screening
  • Brazil coverage

What people use each for

The jobs each tool is most often brought in to do.

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Zimpler
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Zimpler
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Zimpler
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Zimpler

Zimpler

  • A Swedish gambling operator needing deposit and verified identity in a single customer flownot LatchBio
  • A Nordic merchant wanting instant bank payouts rather than card refundsnot LatchBio
  • A trading platform where confirming account ownership before funding is a regulatory requirementnot LatchBio
  • A European operator expanding into Brazil and wanting one provider across both marketsnot LatchBio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing

Zimpler

  • Pricing is not published and is set by industry and risk profile, so smaller merchants cannot benchmark a quote and often discover they are paying well above a general-purpose provider
  • As a payment facilitator carrying merchant risk, it declines or offboards merchants on risk grounds, which makes it a dependency you cannot assume will persist
  • Its strength is concentrated in the Nordics, and coverage in southern and eastern Europe is thinner than pan-European account-to-account specialists
  • Revenue concentration in iGaming ties the provider to a sector under constant regulatory change, so licence changes in one market affect the supplier as well as the merchant
  • Bank transfers have no chargeback protection, so disputes are handled commercially and consumers used to card protections may resist the payment method

Pricing, plan by plan

LatchBio

On request
  • LatchBio PlatformOn request
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Zimpler

On request
  • Zimpler paymentsOn request
    • Per-transaction pricing quoted by industry, risk and volume
    • Separate pricing for payouts and identity verification
    • Merchant underwriting required, with sector restrictions

Which should you pick?

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.

Choose Zimpler if

  • You need bank payments.
  • You work on Web, API.
  • You also want bankid identity.

Questions people ask

Is LatchBio or Zimpler better?
Neither clearly leads. LatchBio starts at On request and Zimpler at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, LatchBio or Zimpler?
LatchBio starts at On request and Zimpler at On request.
Does LatchBio or Zimpler run on more platforms?
LatchBio runs on Web. Zimpler runs on Web, API.
What is LatchBio best used for?
LatchBio is most often used for a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly, an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files, a wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facility, a research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegated. Of those, a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly and an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files are not what Zimpler is typically brought in for.
What can LatchBio do that Zimpler cannot?
LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals. Zimpler covers Bank payments, BankID identity, Payouts, Recurring payments.

Answered from the vendors’ own pages

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Zimpler: Which markets does Zimpler cover?

Sweden and the Nordics primarily, plus the wider EU and Brazil. It is strongest where national electronic identity schemes exist.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Zimpler: Does it handle identity verification?

Yes. In the Nordics it captures BankID identity alongside the payment, which removes a separate verification step.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Zimpler: Is pricing published?

No. It is quoted per merchant based on sector, risk and volume, and merchants must pass underwriting first.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Share

Related pages

Other head to heads